Alfresa First-Half Operating Profit Falls 20% on April Drug-Price Cuts and Rising Logistics Costs, Sales Up 3.5%

Drug wholesaler Alfresa Holdings raised net sales 3.5% to ¥1,582,760 million in the six months to September, but operating profit fell 19.6% to ¥13,029 million as the April 2026 drug-price revision, efforts to correct excessive drug-price gaps and higher logistics and personnel costs weighed. Net profit attributable to owners fell 28.5% to ¥8,240 million.

Alfresa H1 FY3/2027 earnings summary

Wholesale margin squeezed

Alfresa Holdings Corporation (TSE: 2784) reported consolidated results for the first half of FY3/2027, April 1 to September 30, 2026, on November 9, 2026. Ethical Pharmaceuticals Wholesale sales rose 4.2% to ¥1,425,124 million on higher sales of some type 2 diabetes drugs and specialty medicines, but operating profit fell 5.2% to ¥13,986 million because of the April drug-price revision, its work to eliminate uneven price gaps under revised distribution guidelines, and rising logistics and personnel costs. Self-Medication Wholesale sales fell 3.7% to ¥130,582 million and operating profit 41.6% to ¥1,025 million amid consolidation among large drugstore chains and higher logistics costs.

Alfresa bought back ¥14,999 million of its own shares in May 2026, agreed to acquire ear, nose and throat device maker Nagashima Medical Instruments, made an additional investment in regenerative-medicine venture ReeNT, and started operations at a new drug-manufacturing building at Alfresa Pharma's Gunma plant in April. Net assets fell 2.6% to ¥494,734 million after the buyback, and the equity ratio slipped to 32.2%.

Guidance unchanged

Alfresa kept its FY3/2027 forecast of net sales of ¥3,144,000 million (+1.3%), operating profit of ¥33,900 million (-6.3%), ordinary profit of ¥36,600 million (-5.3%) and net profit attributable to owners of ¥20,800 million (-50.2%). It paid an interim dividend of ¥35 and kept its annual forecast of ¥71, up from ¥68.

Alfresa Holdings Corporation — H1 FY3/2027 (April 1 – September 30, 2026), Japanese GAAP, consolidated. Balance-sheet rows compare September 30, 2026 with March 31, 2026; guidance and dividend rows are full-year FY3/2027 against FY3/2026. "—" indicates a figure not disclosed.
MetricH1 FY3/2027H1 FY3/2026Change
Net sales (¥ million)1,582,7601,529,762+3.5%
Operating profit (¥ million)13,02916,207-19.6%
Ordinary profit (¥ million)14,38017,485-17.8%
Net profit attrib. to owners of parent (¥ million)8,24011,521-28.5%
Comprehensive income (¥ million)9,38513,542-30.7%
EPS (¥)46.5363.35-26.6%
Ethical Pharmaceuticals Wholesale — revenue (¥ million)1,425,124—+4.2%
Ethical Pharmaceuticals Wholesale — segment profit (¥ million)13,986—-5.2%
Self-Medication Wholesale — revenue (¥ million)130,582—-3.7%
Self-Medication Wholesale — segment profit (¥ million)1,025—-41.6%
Total assets (¥ million)1,536,4011,507,016+2.0%
Net assets (¥ million)494,734507,903-2.6%
Equity ratio32.2%33.7%-1.5 pt
FY3/2027 guidance — revenue (¥ million)3,144,000—+1.3%
FY3/2027 guidance — operating profit (¥ million)33,900—-6.3%
FY3/2027 guidance — ordinary profit (¥ million)36,600—-5.3%
FY3/2027 guidance — net profit (¥ million)20,800—-50.2%
Annual dividend per share (¥)71.0068.00+4.4%

JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.